A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan : amino acid substitutions in HCV core region as predictor of sustained virological response
A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan : amino acid substitutions in HCV core region as predictor of sustained virological response
